
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is making strong progress in its Genio system launch in the U.S., with a doubling of active high-volume accounts in the quarter and continued rollout of its Genio app software upgrade. The company's focused efforts on reimbursement, including pursuing a new CPT code, bode well for future growth potential. With Q2 net-revenue in line with pre-announced figures and a positive FY26 revenue guidance above market expectations, we remain optimistic about Nyxoah's potential and reiterate an OW rating.
Bears say
Nyxoah is dealing with increased competition and lower than expected financials for the second quarter, with slower revenue growth than expected. Additionally, the company's gross margin and opex spend were both above estimates, and the company has yet to reach its previously stated net revenue and gross margin guidance for FY26. The company's overall high valuation in the medtech category is also contributing to a lowered price target of $7 as a result of a lower valuation multiple applied to FY27 revenue forecast.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares